Direct current stimulation enhances neuronal alpha-synuclein degradation in vitro.
Ammonium Chloride
/ pharmacology
Autophagy
/ genetics
Biomarkers
/ metabolism
Brain-Derived Neurotrophic Factor
/ genetics
Cell Line, Tumor
Cell Shape
Cell Survival
DNA-Binding Proteins
/ genetics
Down-Regulation
Humans
Neurons
/ metabolism
Protein Aggregates
Proteolysis
Rotenone
/ pharmacology
Solubility
Transcranial Direct Current Stimulation
alpha-Synuclein
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 01 2021
26 01 2021
Historique:
received:
09
07
2020
accepted:
08
01
2021
entrez:
27
1
2021
pubmed:
28
1
2021
medline:
18
9
2021
Statut:
epublish
Résumé
Despite transcranial Direct Current Stimulation (DCS) is currently proposed as a symptomatic treatment in Parkinson's disease, the intracellular and molecular mechanisms elicited by this technique are still unknown, and its disease-modifying potential unexplored. Aim of this study was to elucidate the on-line and off-line effects of DCS on the expression, aggregation and degradation of alpha-synuclein (asyn) in a human neuroblastoma cell line under basal conditions and in presence of pharmachologically-induced increased asyn levels. Following DCS, gene and protein expression of asyn and its main autophagic catabolic pathways were assessed by real-time PCR and Western blot, extracellular asyn levels by Dot blot. We found that, under standard conditions, DCS increased monomeric and reduced oligomeric asyn forms, with a concomitant down-regulation of both macroautophagy and chaperone-mediated autophagy. Differently, in presence of rotenone-induced increased asyn, DCS efficiently counteracted asyn accumulation, not acting on its gene transcription, but potentiating its degradation. DCS also reduced intracellular and extracellular asyn levels, increased following lysosomal inhibition, independently from autophagic degradation, suggesting that other mechanisms are also involved. Collectively, these findings suggest that DCS exerts on-line and off-line effects on the expression, aggregation and autophagic degradation of asyn, indicating a till unknown neuroprotective role of tDCS.
Identifiants
pubmed: 33500442
doi: 10.1038/s41598-021-81693-8
pii: 10.1038/s41598-021-81693-8
pmc: PMC7838399
doi:
Substances chimiques
Biomarkers
0
Brain-Derived Neurotrophic Factor
0
DNA-Binding Proteins
0
Protein Aggregates
0
TARDBP protein, human
0
alpha-Synuclein
0
Ammonium Chloride
01Q9PC255D
Rotenone
03L9OT429T
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2197Commentaires et corrections
Type : ErratumIn
Références
Clin Neurophysiol. 2003 Nov;114(11):2220-2; author reply 2222-3
pubmed: 14580622
Sci Rep. 2018 Oct 11;8(1):15165
pubmed: 30310174
Front Aging Neurosci. 2020 May 13;12:134
pubmed: 32595486
Brain Sci. 2019 Dec 23;10(1):
pubmed: 31878058
Clin Neurophysiol. 2003 Apr;114(4):600-4
pubmed: 12686268
J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1105-11
pubmed: 20870863
Mol Neurodegener. 2018 Aug 2;13(1):40
pubmed: 30071902
Mov Disord. 2014 Jul;29(8):1064-9
pubmed: 24789677
eNeuro. 2017 Sep 19;4(5):
pubmed: 28966974
Neurosci Lett. 1999 Jul 23;270(1):45-8
pubmed: 10454142
Brain Stimul. 2015 Nov-Dec;8(6):1223-5
pubmed: 26319357
Brain Stimul. 2018 Jul - Aug;11(4):727-733
pubmed: 29576498
Neurochem Int. 2019 Oct;129:104491
pubmed: 31229553
Cancer. 2014 Feb 15;120(4):480-91
pubmed: 24496866
Brain Stimul. 2016 Sep-Oct;9(5):641-661
pubmed: 27372845
Neurobiol Learn Mem. 2019 May;161:37-45
pubmed: 30735789
Front Neurosci. 2020 Jan 29;14:28
pubmed: 32063834
Front Mol Neurosci. 2016 Dec 23;9:157
pubmed: 28066181
Mov Disord. 2018 Dec;33(12):1972-1973
pubmed: 30423199
Cerebellum Ataxias. 2016 Sep 02;3(1):16
pubmed: 27595007
Neurobiol Learn Mem. 2015 Sep;123:168-78
pubmed: 26070657
Pathophysiology. 2019 Sep - Dec;26(3-4):203-212
pubmed: 30850244
Chin Med J (Engl). 2010 Apr 20;123(8):1086-92
pubmed: 20497720
Mov Disord. 2006 Oct;21(10):1693-702
pubmed: 16817194
Neuron. 2005 Jan 20;45(2):201-6
pubmed: 15664172
Biomed Res Int. 2013;2013:846725
pubmed: 23984410
Sci Rep. 2017 Jan 20;7:41129
pubmed: 28106136
J Clin Neurosci. 2019 May;63:176-181
pubmed: 30723034
Clin Neurophysiol. 2017 Sep;128(9):1774-1809
pubmed: 28709880
Rev Neurosci. 2011;22(4):471-81
pubmed: 21819264
Mov Disord. 2018 Apr;33(4):642-646
pubmed: 29436740
Cerebellum. 2016 Feb;15(1):43-47
pubmed: 26542731
Biochem Biophys Res Commun. 2015 Mar 6;458(2):411-7
pubmed: 25660455
J Neurol. 2009 Aug;256(8):1205-14
pubmed: 19271105
Acta Neuropathol. 2007 Jul;114(1):63-70
pubmed: 17492294
Neurology. 2005 Mar 8;64(5):872-5
pubmed: 15753425
Brain. 2019 May 1;142(5):1176-1194
pubmed: 30938443
Clin Neurophysiol. 2017 Jan;128(1):56-92
pubmed: 27866120
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a009357
pubmed: 22474616
Clin Neurophysiol. 2013 May;124(5):1039-40
pubmed: 23084663
Neurotoxicology. 2016 May;54:161-169
pubmed: 27133439